Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

NCT02272127 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: icotinib

Sponsor

Nanfang Hospital, Southern Medical University